[go: up one dir, main page]

US20170112772A1 - Microcapsules comprising a fat-soluble active substance - Google Patents

Microcapsules comprising a fat-soluble active substance Download PDF

Info

Publication number
US20170112772A1
US20170112772A1 US15/252,835 US201615252835A US2017112772A1 US 20170112772 A1 US20170112772 A1 US 20170112772A1 US 201615252835 A US201615252835 A US 201615252835A US 2017112772 A1 US2017112772 A1 US 2017112772A1
Authority
US
United States
Prior art keywords
active substance
fat
microcapsule
hydrocolloid
content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/252,835
Inventor
Morten Mohn Hansen
Nina Musaeus
Carsten Lynggaard Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39540790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20170112772(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Basf Se filed Critical Basf Se
Priority to US15/252,835 priority Critical patent/US20170112772A1/en
Publication of US20170112772A1 publication Critical patent/US20170112772A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/02—Other edible oils or fats, e.g. shortenings or cooking oils characterised by the production or working-up
    • A23D9/04—Working-up
    • A23D9/05—Forming free-flowing pieces
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/179—Colouring agents, e.g. pigmenting or dyeing agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to microcapsules comprising fat-soluble active substances having a low content of free surface fat, a process for preparing such microcapsules as well as their use and products comprising the microcapsules.
  • Products comprising fat-soluble active substances encapsulated in a hydrocolloid matrix find wide spread use in all kinds of human and animal products, such as food, food supplements, beverages, pharmaceutical, agricultural and veterinary products and personal care products.
  • the purpose is to protect the oxidation sensitive active substance from oxygen and other substances, which attack the substance in order to avoid off-flavour and loss of physiological activity, e.g. during transport, and to increase the shelf life of the products.
  • an important and acknowledged quality parameter is the content of free surface fat. If the product is not substantially free of free surface fat, e.g. if the content of free surface fat in a product comprising polyunsatutared fatty acids (PUFA's) is more than 1-2%, the quality of the product is significantly impaired and the product will quickly deteriorate through oxidation. PUFA-products complying with this quality parameter normally can not hold more than 25-30% of active substance. Besides, products comprising an increased content of fat-soluble active substance must traditionally be produced by using also an increased amount of hydrocolloid.
  • PUFA's polyunsatutared fatty acids
  • Vega et al in Int. Dairy Jour. (2007) Vol. 17, No. 6, pages 683-695 describes spray drying of an anhydrous milk fat emulsion stabilized by caseinate or milk protein isolate with trehalose or lactose as encapsulants.
  • the solvent extractable surface free fat values for the spray dried emulsions are determined, and it appears that the higher oil-to-protein ratios, the higher surface free fat.
  • WO 94/01001 describes microencapsulated oil and fat products, wherein a ratio oil-to-caseinat between about 2.25:1 and 2.75:1 is used. The resulting products hold e.g. 25% fat or oil.
  • WO 01/74175 describes encapsulated oil products with a rather high content of oil of up to 60%.
  • the resulting products have a high content of free surface fat and/or a relatively high content of hydrocolloid.
  • the object of the present invention is to provide microcapsules having both a high content of fat-soluble active substance and a desirable low content of free surface fat as well as a new process for preparation thereof.
  • a further object of the invention is to provide microcapsules with a high content of fat-soluble active substance wherein a corresponding increase in the content of hydrocolloid is avoid.
  • the present invention relates to a microcapsule comprising at least one fat-soluble active substance selected from provitamins, vitamins and esters thereof, monounsaturated fatty acids, oils comprising polyunsaturated fatty acids (PUFA oils), carotenoids and benzoquinones embedded in a matrix comprising a hydrocolloid and optionally one or more other matrix components, wherein the content of active substance(s) is from 30 to 60% of total weight of the microcapsule, and wherein the ratio between said fat-soluble active substance(s) and said hydrocolloid is at least 4:1.
  • PUFA oils polyunsaturated fatty acids
  • the invention further relates to a process of preparing a microcapsule, which process comprises the steps of
  • the product is a PUFA-product
  • an amount of at least 30%, 40% PUFA or even 60% can be included in the product while simultaneously keeping the content of free surface fat as low as 2° A) or even 1%.
  • the content of free surface fat is less than 1%, e.g. less than 0.5% or less than 0.3%, 0.2% or 0.1% of the total weight of the microcapsule.
  • the process of the invention it has also surprisingly become possible to increase the amount of active substance without increasing the amount of hydrocolloid correspondingly.
  • the conventional process used attempts to include a higher amount of active substance also required the use of higher amounts of hydrocolloid.
  • the process used for preparing the microcapsules of the invention is cost-efficient.
  • the encapsulation efficiency improves, because less free fat on the surface of the microcapsule is subjected to oxidation. Therefore, the microcapsule becomes more mechanically and chemically stable during storage, transport and further processing into tablets and extrudates or use in food mixes.
  • microcapsules as used herein means particles each comprising a matrix material having embedded therein a plurality of solid or liquid micro particles or solute molecules.
  • Microcapsules usually have a mean diameter of about 5 mm or smaller, e.g. between 1 mm and 0.05 mm, such as between 0.6 and 0.1 mm. They can also have a diameter e.g. between 2 mm and 0.01 mm, such as between 1.5 mm and 0.2 mm.
  • emulsion covers both an emulsion meaning a mixture comprising liquid particles (e.g. oil droplets) dispersed in a liquid medium, e.g. water/aqueous solution, or a suspension meaning solid particles dispersed in an liquid medium, e.g. water/aqueous solution.
  • liquid particles e.g. oil droplets
  • suspension meaning solid particles dispersed in an liquid medium, e.g. water/aqueous solution.
  • free surface fat or “free fat” as used herein means the fat that is readily extractable by organic solvent under specified conditions. This fat is susceptible to oxidization. The free fat is located on the particle surface, as fat globules just below the particle surface or in contact with capillaries or as dissolution fat almost touching already extracted fat globules.
  • the free surface fat as defined in connection with the invention is determined as described in the example.
  • the content of active substance(s) is at least 32.5%, such as at least 35%, at least 37.5% or at least 40% of total weight of the microcapsule. It may also be at least 42.5%, at least 45% or at least 47.5% of total weight of the microcapsule.
  • the ratio between said fat-soluble active substance(s) and said hydrocolloid is at least 5:1, e.g. at least 6:1, at least 7:1 or at least 8:1.
  • the fat-soluble active substances comprised in the microcapsule of the invention or the microcapsule prepared according to the present invention is a substance which during storage, transport, handling and use requires protection, e.g. from oxygen, moisture, light radiation, and physical influences, in order to avoid physical and chemical decomposition of the substance.
  • These active substances are further defined as being active in either a chemical or biological system.
  • Active substances suitable for use in connection with the present invention are provitamins and vitamins, e.g. vitamin A and esters thereof, vitamin E and esters thereof, e.g. E-acetate, vitamin D and K, e.g. D2, D3 and K1, monounsaturated fatty acids and polyunsaturated fatty acids (PUFA's), which may be added in the form of fish oil containing i.a. the (n-3) fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), conjugated linolenic acid (CLA), carotenoids, e.g.
  • provitamins and vitamins e.g. vitamin A and esters thereof, vitamin E and esters thereof, e.g. E-acetate, vitamin D and K, e.g. D2, D3 and K1, monounsaturated fatty acids and polyunsaturated fatty acids (PUFA's), which may be added in the form of fish oil
  • ⁇ -carotene lutein, lycopene, ⁇ -cryptoxanthin, astaxanthin, cantaxanthin, citranaxanthin and zeaxanthin, curcumin and benzoquinones, e.g. coenzyme Q10 (ubidecarenone).
  • coenzyme Q10 ubidecarenone
  • the fat soluble active substance is vitamin E or E-acetate, vitamin A, vitamin D2, D3 or K1, a monounsaturated fatty acid or a PUFA (an oil comprising poly unsaturated fatty acids), ⁇ -carotene, lycopene, lutein or Q10.
  • the matrix hydrocolloid of the invention may be any conventional material, such as a protein, e.g. caseinate, whey protein, milk protein or hydrolysates, naturally occurring and modified polysaccharides and naturally occurring hydrocolloids, e.g. alginate, carrageenan, gelatine, gum acacia, modified gum acacia, pectins, modified pectins or mixtures.
  • a protein e.g. caseinate, whey protein, milk protein or hydrolysates
  • naturally occurring and modified polysaccharides and naturally occurring hydrocolloids e.g. alginate, carrageenan, gelatine, gum acacia, modified gum acacia, pectins, modified pectins or mixtures.
  • Starch derived from a natural source such as potato, wheat, maize, tapioca and rice, and modified starch are other examples of suitable matrix hydrocolloids, e.g. sodium octenyl succinate modified starch
  • the hydrocolloid is sodium or potassium caseinate.
  • said fat-soluble active substance(s) and said hydrocolloid is used in a ratio of at least 5:1 or at least 6:1, e.g. at least 7:1 or at least 8:1.
  • the matrix can optionally comprise further components, such as dissolved carbohydrates, e.g. sorbitol and sucrose, and/or an antioxidant.
  • the microcapsule may further contain conventional additives such as antioxidants, e.g. t-butylhydroxytoluene (BHT), t-butylhydroxyanisole (BHA), ascorbic acid, ascorbyl palmitate, sodium ascorbate, citric acid, sodium citrate, EDTA or its salts, tocopherols, TBHQ, ethoxyquine, propyl gallate, and extracts from herbs, i.a. rosemary or oregano extract; anti-caking agents, e.g. tri-calcium phosphate and silicates, i.a. silicon dioxide and sodium aluminium silicate; plasticizers, e.g.
  • antioxidants e.g. t-butylhydroxytoluene (BHT), t-butylhydroxyanisole (BHA), ascorbic acid, ascorbyl palmitate, sodium ascorbate, citric acid, sodium citrate, EDTA or its salts, tocopherols, TBHQ,
  • carbohydrates and carbohydrate alcohols examples of which are saccharose, glucose, fructose, lactose, invert sugar, sorbitol, mannitol, Trehalose, Tagatose, Pullulan, Raftilose (oligofructose), dextrin, maltodextrin, glycerin, and mixtures thereof, such as saccharose, Trehalose, Pullulan, dextrin and Raftilose and mixtures thereof, emulsifiers and surfactants, e.g. ascorbyl palmitate, sucrose esters, mono- and diglycerides of fatty acids and derivatives thereof, and lecithin.
  • saccharose glucose, fructose, lactose, invert sugar
  • sorbitol mannitol
  • Trehalose Tagatose
  • Pullulan Raftilose (oligofructose)
  • dextrin maltodextrin
  • glycerin and
  • the dividing and drying of the solution or dispersion to produce a mass of particles can be done in any conventional way, such as spray cooling, spray drying or sheet drying and crushing, see e.g. WO 91/06292.
  • a powdering agent such as corn starch, is fed to the microcapsules during the finely dividing and drying step.
  • the present invention also relates to a product comprising the microcapsule according to the present invention.
  • this product is a food, a food supplement, a beverage, a pharmaceutical or veterinary product, a feed or feed supplement, a personal care product or a household product.
  • the invention relates to the use of microcapsules of the invention for the manufacture of tablets or other solid masses containing an active substance.
  • the water soluble ingredients including the matrix components, are added to hot water and dissolved under agitation.
  • the fat-soluble ingredients are mixed and then added to the aqueous phase and the mixture is treated to prepare a solution or dispersion.
  • the solution or dispersion is diluted, if necessary, to an appropriate viscosity before the solution or dispersion is finely divided and dried by a conventional method.
  • the free surface fat is determined by extraction from the final microcapsule product by a suitable solvent, such as carbontetrachloride, petroleum ether or n-pentane.
  • a suitable solvent such as carbontetrachloride, petroleum ether or n-pentane.
  • the dispersion was homogenised in a rotor/stator system; alternatively a high pressure homogeniser can be applied; and diluted to a sprayable viscosity.
  • the dispersion was atomised in a spray drying tower, where the dispersion particles were covered with a thin layer of starch and dried.
  • 332 g potassium caseinate, 1356 g sucrose and 252 g sodium ascorbate were dissolved in 1100 ml water at 65° C. under agitation.
  • 3324 g PUFA oil (comprising 60 mg/g eicosapentaenoic acid (EPA) and 260 mg/g docosahexaenoic acid (DHA)) was mixed with an antioxidant, heated to 65° C. and added to the aqueous solution and stirred.
  • the dispersion was homogenised in a rotor/stator; alternatively a high pressure homogeniser can be applied; and diluted to a sprayable viscosity.
  • 3000 g potassium caseinate, 6000 g sucrose and 1356 g sodium ascorbate were dissolved in 1400 ml water at 65° C. under agitation.
  • 6002 g PUFA oil (comprising 60 mg/g eicosapentaenoic acid (EPA) and 260 mg/g docosahexaenoic acid (DHA)) was mixed with an antioxidant, heated to 65° C. and added to the aqueous solution and stirred.
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • the dispersion was homogenised well in a rotor/stator; alternatively a high pressure homogeniser can be applied; and diluted to a sprayable viscosity.
  • the dispersion was atomised in a spray drying tower, where the dispersion particles were covered with a thin layer of starch and dried.
  • the dispersion was homogenised well in a rotor/stator system; alternatively a high pressure homogeniser can be applied; and diluted to a sprayable viscosity.
  • the dispersion was atomised in a spray drying tower, where the dispersion particles were covered with a thin layer of starch and dried.
  • a PUFA product with PUFA oil:caseinate ratio of 3.5:1 was prepared in a similar way.
  • the resulting dry powder had the following characteristics:

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Animal Husbandry (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Edible Oils And Fats (AREA)
  • Fats And Perfumes (AREA)

Abstract

The invention relates to microcapsule comprising at least one fat-soluble active substance selected from provitamins, vitamins and esters thereof, monounsaturated fatty acids, polyunsaturated fatty acids (PUFA's), carotenoids and benzoquinones embedded in a matrix comprising a hydrocolloid and optionally one or more other matrix components, wherein the content of active substance(s) is from 30 to 60% of total weight of the microcapsule, and wherein the ratio between said fat-soluble active substance(s) and said hydrocolloid is at least 4:1, as well as a process for preparing such microcapsules.
The microcapsules of the invention may be used for the preparation of tablets, food products and other products including an active substance.

Description

    FIELD OF INVENTION
  • The present invention relates to microcapsules comprising fat-soluble active substances having a low content of free surface fat, a process for preparing such microcapsules as well as their use and products comprising the microcapsules.
    • BACKGROUND OF THE INVENTION
  • Products comprising fat-soluble active substances encapsulated in a hydrocolloid matrix find wide spread use in all kinds of human and animal products, such as food, food supplements, beverages, pharmaceutical, agricultural and veterinary products and personal care products. The purpose is to protect the oxidation sensitive active substance from oxygen and other substances, which attack the substance in order to avoid off-flavour and loss of physiological activity, e.g. during transport, and to increase the shelf life of the products.
  • When encapsulating fat-soluble active substances an important and acknowledged quality parameter is the content of free surface fat. If the product is not substantially free of free surface fat, e.g. if the content of free surface fat in a product comprising polyunsatutared fatty acids (PUFA's) is more than 1-2%, the quality of the product is significantly impaired and the product will quickly deteriorate through oxidation. PUFA-products complying with this quality parameter normally can not hold more than 25-30% of active substance. Besides, products comprising an increased content of fat-soluble active substance must traditionally be produced by using also an increased amount of hydrocolloid.
  • Hogan et al in J. Agric. Food Chem. (2001) Vol 49, No. 4, pages 1934-1938, describes microencapsulating properties of sodium caseinate when used in emulsions of soy oils. The effect of increasing the oil/protein ratio on protein load is tested, and it appears that increasing the oil/protein ratio from 0.25 to 3.0 resulted in a progressive decrease in microencapsulation efficiency.
  • Vega et al in Jour. Dairy Sci. (2006) Vol. 89, No. 2, pages 383-401 describes emulsions with oil-to-protein ratios ranging from 0.25 to 5. Surface fat was reduced from 30% to less than 5%, when lactose was added to an emulsion containing 30% oil.
  • Vega et al in Int. Dairy Jour. (2007) Vol. 17, No. 6, pages 683-695 describes spray drying of an anhydrous milk fat emulsion stabilized by caseinate or milk protein isolate with trehalose or lactose as encapsulants. The solvent extractable surface free fat values for the spray dried emulsions are determined, and it appears that the higher oil-to-protein ratios, the higher surface free fat.
  • WO 94/01001 describes microencapsulated oil and fat products, wherein a ratio oil-to-caseinat between about 2.25:1 and 2.75:1 is used. The resulting products hold e.g. 25% fat or oil.
  • WO 01/74175 describes encapsulated oil products with a rather high content of oil of up to 60%. The resulting products have a high content of free surface fat and/or a relatively high content of hydrocolloid.
  • The object of the present invention is to provide microcapsules having both a high content of fat-soluble active substance and a desirable low content of free surface fat as well as a new process for preparation thereof.
  • A further object of the invention is to provide microcapsules with a high content of fat-soluble active substance wherein a corresponding increase in the content of hydrocolloid is avoid.
  • It is a further object of the invention to provide microcapsules having storage and transportation stability as well as mechanical strength and improved performance during the further processing into tablets, extrudates and the like.
    • SUMMARY OF THE INVENTION
  • The present invention relates to a microcapsule comprising at least one fat-soluble active substance selected from provitamins, vitamins and esters thereof, monounsaturated fatty acids, oils comprising polyunsaturated fatty acids (PUFA oils), carotenoids and benzoquinones embedded in a matrix comprising a hydrocolloid and optionally one or more other matrix components, wherein the content of active substance(s) is from 30 to 60% of total weight of the microcapsule, and wherein the ratio between said fat-soluble active substance(s) and said hydrocolloid is at least 4:1.
  • The invention further relates to a process of preparing a microcapsule, which process comprises the steps of
      • providing a solution or dispersion of said hydrocolloid and said optionally other matrix components,
      • adding to said solution or dispersion said at least one fat-soluble active substance selected from provitamins, vitamins and esters thereof, monounsaturated fatty acids, oils comprising polyunsaturated fatty acids (PUFA oils), carotenoids and benzoquinones,
      • treating the mixture thus obtained to prepare a solution or dispersion of said at least one active substance in said matrix,
      • finely dividing and drying the mixture thus obtained to prepare a mass of particles each containing said at least one active substance embedded in said matrix,
        wherein said at least one active substance and said hydrocolloid are used in a ratio of at least 4:1.
  • It has surprisingly been found that by using a high oil-to-hydrocolloid ratio in the preparation of the microcapsule, it becomes possible to include a much higher amount of fat-soluble active substance in the final product, and at the same time still maintain a low content of free surface fat. If for instance the product is a PUFA-product, an amount of at least 30%, 40% PUFA or even 60% can be included in the product while simultaneously keeping the content of free surface fat as low as 2° A) or even 1%. In most cases the content of free surface fat is less than 1%, e.g. less than 0.5% or less than 0.3%, 0.2% or 0.1% of the total weight of the microcapsule.
  • By the conventional process used until now attempts to include a higher amount than 25-30% fat-soluble active substance often lead to an undesirable substantial increase in free surface fat.
  • By the process of the invention it has also surprisingly become possible to increase the amount of active substance without increasing the amount of hydrocolloid correspondingly. By the conventional process used attempts to include a higher amount of active substance also required the use of higher amounts of hydrocolloid. Thus, the process used for preparing the microcapsules of the invention is cost-efficient.
  • When the amount of free surface fat decreases the encapsulation efficiency improves, because less free fat on the surface of the microcapsule is subjected to oxidation. Therefore, the microcapsule becomes more mechanically and chemically stable during storage, transport and further processing into tablets and extrudates or use in food mixes.
  • The term “microcapsules” as used herein means particles each comprising a matrix material having embedded therein a plurality of solid or liquid micro particles or solute molecules. Microcapsules usually have a mean diameter of about 5 mm or smaller, e.g. between 1 mm and 0.05 mm, such as between 0.6 and 0.1 mm. They can also have a diameter e.g. between 2 mm and 0.01 mm, such as between 1.5 mm and 0.2 mm.
  • The term “dispersion” as used herein covers both an emulsion meaning a mixture comprising liquid particles (e.g. oil droplets) dispersed in a liquid medium, e.g. water/aqueous solution, or a suspension meaning solid particles dispersed in an liquid medium, e.g. water/aqueous solution.
  • The terms “free surface fat” or “free fat” as used herein means the fat that is readily extractable by organic solvent under specified conditions. This fat is susceptible to oxidization. The free fat is located on the particle surface, as fat globules just below the particle surface or in contact with capillaries or as dissolution fat almost touching already extracted fat globules. The free surface fat as defined in connection with the invention is determined as described in the example.
    • DETAILED DESCRIPTION OF THE INVENTION
  • In one embodiment of the invention the content of active substance(s) is at least 32.5%, such as at least 35%, at least 37.5% or at least 40% of total weight of the microcapsule. It may also be at least 42.5%, at least 45% or at least 47.5% of total weight of the microcapsule.
  • In other embodiments the ratio between said fat-soluble active substance(s) and said hydrocolloid is at least 5:1, e.g. at least 6:1, at least 7:1 or at least 8:1.
  • The fat-soluble active substances comprised in the microcapsule of the invention or the microcapsule prepared according to the present invention is a substance which during storage, transport, handling and use requires protection, e.g. from oxygen, moisture, light radiation, and physical influences, in order to avoid physical and chemical decomposition of the substance. These active substances are further defined as being active in either a chemical or biological system.
  • Active substances suitable for use in connection with the present invention are provitamins and vitamins, e.g. vitamin A and esters thereof, vitamin E and esters thereof, e.g. E-acetate, vitamin D and K, e.g. D2, D3 and K1, monounsaturated fatty acids and polyunsaturated fatty acids (PUFA's), which may be added in the form of fish oil containing i.a. the (n-3) fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), conjugated linolenic acid (CLA), carotenoids, e.g. β-carotene, lutein, lycopene, β-cryptoxanthin, astaxanthin, cantaxanthin, citranaxanthin and zeaxanthin, curcumin and benzoquinones, e.g. coenzyme Q10 (ubidecarenone).
  • According to one embodiment the fat soluble active substance is vitamin E or E-acetate, vitamin A, vitamin D2, D3 or K1, a monounsaturated fatty acid or a PUFA (an oil comprising poly unsaturated fatty acids), β-carotene, lycopene, lutein or Q10.
  • The matrix hydrocolloid of the invention may be any conventional material, such as a protein, e.g. caseinate, whey protein, milk protein or hydrolysates, naturally occurring and modified polysaccharides and naturally occurring hydrocolloids, e.g. alginate, carrageenan, gelatine, gum acacia, modified gum acacia, pectins, modified pectins or mixtures. Starch derived from a natural source, such as potato, wheat, maize, tapioca and rice, and modified starch are other examples of suitable matrix hydrocolloids, e.g. sodium octenyl succinate modified starch.
  • In one embodiment the hydrocolloid is sodium or potassium caseinate.
  • In one embodiment of the process of the invention for preparing the microcapsule said fat-soluble active substance(s) and said hydrocolloid is used in a ratio of at least 5:1 or at least 6:1, e.g. at least 7:1 or at least 8:1.
  • The matrix can optionally comprise further components, such as dissolved carbohydrates, e.g. sorbitol and sucrose, and/or an antioxidant.
  • The microcapsule may further contain conventional additives such as antioxidants, e.g. t-butylhydroxytoluene (BHT), t-butylhydroxyanisole (BHA), ascorbic acid, ascorbyl palmitate, sodium ascorbate, citric acid, sodium citrate, EDTA or its salts, tocopherols, TBHQ, ethoxyquine, propyl gallate, and extracts from herbs, i.a. rosemary or oregano extract; anti-caking agents, e.g. tri-calcium phosphate and silicates, i.a. silicon dioxide and sodium aluminium silicate; plasticizers, e.g. carbohydrates and carbohydrate alcohols, examples of which are saccharose, glucose, fructose, lactose, invert sugar, sorbitol, mannitol, Trehalose, Tagatose, Pullulan, Raftilose (oligofructose), dextrin, maltodextrin, glycerin, and mixtures thereof, such as saccharose, Trehalose, Pullulan, dextrin and Raftilose and mixtures thereof, emulsifiers and surfactants, e.g. ascorbyl palmitate, sucrose esters, mono- and diglycerides of fatty acids and derivatives thereof, and lecithin.
  • The dividing and drying of the solution or dispersion to produce a mass of particles can be done in any conventional way, such as spray cooling, spray drying or sheet drying and crushing, see e.g. WO 91/06292.
  • In one embodiment of the process of the invention a powdering agent, such as corn starch, is fed to the microcapsules during the finely dividing and drying step.
  • The present invention also relates to a product comprising the microcapsule according to the present invention. According to one embodiment of the invention, this product is a food, a food supplement, a beverage, a pharmaceutical or veterinary product, a feed or feed supplement, a personal care product or a household product.
  • The products prepared according to the method of the invention are as well suitable for a wide variety of applications, such as the ones described above.
  • Finally, the invention relates to the use of microcapsules of the invention for the manufacture of tablets or other solid masses containing an active substance.
  • The process of the invention may be carried out in accordance with the following general recipe or as shown in the examples:
  • The water soluble ingredients, including the matrix components, are added to hot water and dissolved under agitation. The fat-soluble ingredients are mixed and then added to the aqueous phase and the mixture is treated to prepare a solution or dispersion. The solution or dispersion is diluted, if necessary, to an appropriate viscosity before the solution or dispersion is finely divided and dried by a conventional method.
  • If applicable a powdering agent is added during the diving and drying.
  • The free surface fat is determined by extraction from the final microcapsule product by a suitable solvent, such as carbontetrachloride, petroleum ether or n-pentane.
  • The invention will now be described in further detail with reference to the following examples.
    • EXAMPLES Test Method: Determination of Free Surface Fat
  • Principle: The microcapsules are dispersed in petroleum ether, whereby the amount of fat which is not encapsulated dissolves and is determined by means of weight analysis. Free fat is expressed as the extracted amount of fat in relation to the weighed amount of product.
  • Method: Weigh 10.00 g (±0.50 g) product into a 250 mL Erlenmeyer flask.
  • Add 50.0 mL petroleum ether to the flask and shake for a few seconds. Decant the petroleum ether into a counterbalanced 100 mL Erlenmeyer flask through a Whatman No. 4 paper filter, which has been moistened with petroleum ether.
  • Repeat the procedure with another 50 mL petroleum ether and again with 2×10 mL petroleum ether.
  • Evaporate the entire amount of petroleum under nitrogen at max. 40° C. and place the flask in an incubator at 105° C. for one hour and allow to cool in a desiccators.
  • Weigh the flask in grams (4 decimals).
  • Calculate the content of free fat (%) in the samples by the following equation:
  • ( m 2 - m 1 ) * 100 m sample m 1 = Weight of flask ( g ) m 2 = Weight of flask with free fat ( g ) m sample = Weighed sample ( g )
    • Examples According to the Invention Example 1 A PUFA Product with PUFA Oil:Caseinate Ratio 8:1
  • 389 g potassium caseinate, 1700 g sucrose and 312 g sodium ascorbate were dissolved in 1200 ml water at 65° C. under agitation. 3117 g PUFA oil (comprising 60 mg/g eicosapentaenoic acid (EPA) and 260 mg/g docosahexaenoic acid (DHA)) was mixed with an antioxidant, heated to 65° C. and added to the aqueous solution and stirred.
  • The dispersion was homogenised in a rotor/stator system; alternatively a high pressure homogeniser can be applied; and diluted to a sprayable viscosity.
  • Subsequently the dispersion was atomised in a spray drying tower, where the dispersion particles were covered with a thin layer of starch and dried.
  • The resulting dry powder had the following characteristics:
    • Content of PUFA oil: 42.0%, Free Fat: 0.2% Example 2 A PUFA Product with PUFA Oil:Caseinate Ratio 10:1
  • 332 g potassium caseinate, 1356 g sucrose and 252 g sodium ascorbate were dissolved in 1100 ml water at 65° C. under agitation. 3324 g PUFA oil (comprising 60 mg/g eicosapentaenoic acid (EPA) and 260 mg/g docosahexaenoic acid (DHA)) was mixed with an antioxidant, heated to 65° C. and added to the aqueous solution and stirred.
  • The dispersion was homogenised in a rotor/stator; alternatively a high pressure homogeniser can be applied; and diluted to a sprayable viscosity.
  • Subsequently the dispersion was atomised in a spray drying tower, where the dispersion particles were covered with a thin layer of starch and dried.
  • The resulting dry powder had the following characteristics:
    • Content of PUFA oil: 45.9%, Free Fat: 0.27%
  • Dispersions and microcapsules with other ratios of fat-soluble active substance/hydrocolloid were prepared in a similar way. The results are given in Table 1.
    • Example 3
  • PUFA products with other ratios of PUFA oil:caseinate were prepared in a similar way. The results are given in the Table.
  • TABLE
    PUFA oil: Total fat in Free fat in
    caseinate final dry final dry
    Target Ratio product product
    % oil w:w % %
    35%  6:1 36.0 0.16
    40%  4:1 43.0 1.81
    40%  5:1 42.9 1.08
    40%  6:1 43.8 0.76
    40%  8:1 42.0 0.22
    45%  8:1 48.1 1.03
    45% 10:1 47.3 0.71
    • Comparative Examples Comparative Example 1 A PUFA Product with PUFA Oil:Caseinate Ratio 2:1
  • 3000 g potassium caseinate, 6000 g sucrose and 1356 g sodium ascorbate were dissolved in 1400 ml water at 65° C. under agitation. 6002 g PUFA oil (comprising 60 mg/g eicosapentaenoic acid (EPA) and 260 mg/g docosahexaenoic acid (DHA)) was mixed with an antioxidant, heated to 65° C. and added to the aqueous solution and stirred.
  • The dispersion was homogenised well in a rotor/stator; alternatively a high pressure homogeniser can be applied; and diluted to a sprayable viscosity.
  • Subsequently the dispersion was atomised in a spray drying tower, where the dispersion particles were covered with a thin layer of starch and dried.
  • The resulting dry powder had the following characteristics:
    • Content of PUFA: 26.8%, Free Fat: 0.04% Comparative Example 2 A PUFA Product with PUFA Oil:Caseinate Ratio 3:1
  • 487 g potassium caseinate, 492 g sucrose and 146 g sodium ascorbate were dissolved in 1400 ml water at 65° C. under agitation. 1460 g PUFA oil (comprising 60 mg/g eicosapentaenoic acid (EPA) and 260 mg/g docosahexaenoic acid (DHA)) was mixed with an antioxidant, heated to 65° C. and added to the aqueous solution and stirred.
  • The dispersion was homogenised well in a rotor/stator system; alternatively a high pressure homogeniser can be applied; and diluted to a sprayable viscosity.
  • Subsequently the dispersion was atomised in a spray drying tower, where the dispersion particles were covered with a thin layer of starch and dried.
  • The resulting dry powder had the following characteristics:
    • Content of PUFA: 45.9%, Free Fat: 2.68% Comparative Example 3
  • A PUFA product with PUFA oil:caseinate ratio of 3.5:1 was prepared in a similar way. The resulting dry powder had the following characteristics:
    • Content of PUFA: 49.4%, Free Fat: 13.6%

Claims (13)

1-26. (canceled)
27. A microcapsule comprising at least one fat-soluble active substance selected from provitamins, vitamins and esters thereof, monounsaturated fatty acids, oils comprising polyunsaturated fatty acids (PUFA oils), carotenoids and benzoquinones embedded in a matrix comprising a hydrocolloid and optionally one or more other matrix components, wherein the content of active substance(s) is from 30 to 45% of total weight of the microcapsule, and wherein the ratio between said fat-soluble active substance(s) and said hydrocolloid is at least 6:1, and wherein the content of free surface fat is 2% or less.
28. The microcapsule of claim 27, wherein the content of active substance(s) is at least 35% of total weight of the microcapsule.
29. The microcapsule of claim 27, wherein the content of active substance(s) is at least 40% of total weight of the microcapsule.
30. The microcapsule of claim 27, wherein the ratio between said fat-soluble active substance(s) and said hydrocolloid is from 6:1 to 8:1.
31. The microcapsule of claim 27, where in the hydrocolloid is sodium or potassium caseinate.
32. The microcapsule of claim 27, wherein the matrix further contains antioxidants.
33. The microcapsule of claim 27, wherein the content of free surface fat in the microcapsule is less than 1% by weight based on the microcapsule.
34. A process of preparing the microcapsule of claim 27, which process comprises the steps of
providing a solution or dispersion of said hydrocolloid and said optionally other matrix components,
adding to said solution or dispersion said at least one fat-soluble active substance,
treating the mixture thus obtained to prepare a solution or dispersion of said at least one active substance in said matrix,
finely dividing and drying the mixture thus obtained to prepare a mass of particles each containing said at least one active substance embedded in said matrix,
wherein said at least one active substance and said hydrocolloid are used in a ratio of at least 6:1.
35. The process of claim 34, wherein said at least one active substance and said hydrocolloid are used in a ratio of from 6:1 to 8:1.
36. A product comprising the microcapsule of claim 27.
37. A microcapsule comprising at least one fat-soluble active substance selected from the group consisting of monounsaturated fatty acids and oils comprising polyunsaturated fatty acids (PUFA oils) embedded in a matrix comprising a hydrocolloid selected from the group consisting of caseinates; further comprising a carbohydrate and optionally one or more other matrix components, wherein the content of active substance(s) is from 30 to 45% of total weight of the microcapsule, and wherein the ratio between said fat-soluble active substance(s) and said hydrocolloid is at least 6:1, and wherein the content of free surface fat is 2% or less.
38. A microcapsule comprising at least one fat-soluble active substance selected from provitamins, vitamins and esters thereof, monounsaturated fatty acids, oils comprising polyunsaturated fatty acids (PUFA oils), carotenoids and benzoquinones embedded in a matrix comprising a hydrocolloid and optionally one or more other matrix components, wherein the content of active substance(s) is from 30 to 45% of total weight of the microcapsule, and wherein the ratio between said fat-soluble active substance(s) and said hydrocolloid is at least 6:1.
US15/252,835 2007-12-21 2016-08-31 Microcapsules comprising a fat-soluble active substance Abandoned US20170112772A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/252,835 US20170112772A1 (en) 2007-12-21 2016-08-31 Microcapsules comprising a fat-soluble active substance

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07123992 2007-12-21
EP07123992.5 2007-12-21
PCT/EP2008/067887 WO2009080702A1 (en) 2007-12-21 2008-12-18 Microcapsules comprising a fat -soluble active substance
US80966410A 2010-09-30 2010-09-30
US15/252,835 US20170112772A1 (en) 2007-12-21 2016-08-31 Microcapsules comprising a fat-soluble active substance

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US12/809,664 Continuation US9445997B2 (en) 2007-12-21 2008-12-18 Microcapsules comprising a fat-soluble active substance
PCT/EP2008/067887 Continuation WO2009080702A1 (en) 2007-12-21 2008-12-18 Microcapsules comprising a fat -soluble active substance

Publications (1)

Publication Number Publication Date
US20170112772A1 true US20170112772A1 (en) 2017-04-27

Family

ID=39540790

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/809,664 Active 2030-11-28 US9445997B2 (en) 2007-12-21 2008-12-18 Microcapsules comprising a fat-soluble active substance
US15/252,835 Abandoned US20170112772A1 (en) 2007-12-21 2016-08-31 Microcapsules comprising a fat-soluble active substance

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/809,664 Active 2030-11-28 US9445997B2 (en) 2007-12-21 2008-12-18 Microcapsules comprising a fat-soluble active substance

Country Status (8)

Country Link
US (2) US9445997B2 (en)
EP (1) EP2234502B2 (en)
JP (2) JP2011508591A (en)
CN (1) CN101902922B (en)
AU (1) AU2008340061B2 (en)
DK (1) DK2234502T4 (en)
ES (1) ES2632132T5 (en)
WO (1) WO2009080702A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008340061B2 (en) * 2007-12-21 2011-07-14 Basf Se Microcapsules comprising a fat -soluble active substance
CN103987279A (en) * 2011-11-10 2014-08-13 科劳弗股份有限公司 Encapsulation of food ingredients supplements and pharmaceuticals
WO2013107607A1 (en) * 2012-01-19 2013-07-25 Dsm Ip Assets B.V. Beadlets comprising hop acid salts in a protein matrix
WO2013107608A1 (en) * 2012-01-19 2013-07-25 Dsm Ip Assets B.V. Beadlets comprising hop acid salts in a starch matrix
US20130202740A1 (en) * 2012-02-08 2013-08-08 Pepsico, Inc. Acidic Aqueous Product Comprising Oil-Containing Microcapsules and Method for the Manufacture Thereof
KR102152751B1 (en) * 2012-09-28 2020-09-07 (주)아모레퍼시픽 Microcapsule containing glycoprotein of plant origin
CN108308616A (en) * 2013-03-28 2018-07-24 帝斯曼知识产权资产管理有限公司 It is suitble to the lutein composition of infant food preparation
CA2922242C (en) * 2013-08-29 2019-08-13 Abbott Laboratories Nutritional composition having lipophilic compounds with improved solubility and bioavailability
MX378687B (en) * 2014-05-05 2025-03-11 Basf Se FAT-SOLUBLE VITAMIN FORMULATION.
CN104522171B (en) * 2014-12-17 2018-10-12 光明乳业股份有限公司 A kind of fish oil composition, preparation method and the milk powder containing it
CN107205446A (en) * 2015-02-06 2017-09-26 巴斯夫欧洲公司 Microcapsules comprising lutein or lutein ester
GB201509606D0 (en) * 2015-06-03 2015-07-15 Anabio Technologies Ltd Microencapsulates containing stabilised marine-derived oil, and methods for production thereof
DK3328214T3 (en) 2015-07-29 2020-04-27 Abbott Lab NUTRITIVE PRODUCTS WITH IMPROVED LIPOFIL SOLUBILITY AND BIODELIVITY IN A EASY MIXABLE FORM
WO2017063101A1 (en) * 2015-10-12 2017-04-20 浙江医药股份有限公司新昌制药厂 Method of preparing highly stable microcapsule powder or microparticles containing fat-soluble nutrient having increased double bonds
WO2017148907A1 (en) * 2016-03-02 2017-09-08 Basf Se Vibration droplet formation
US20170258710A1 (en) * 2016-03-11 2017-09-14 Intelgenx Corp. Montelukast transmucosal film
CN106360723A (en) * 2016-10-20 2017-02-01 常州迪纳托生物科技有限公司 Industrial production method for lycopene microcapsule powder
US20210077446A1 (en) * 2016-12-13 2021-03-18 Dsm Ip Assets B.V. Pufa salt formulations (ii)
EP3351118A1 (en) * 2017-01-20 2018-07-25 Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory Fat-soluble active ingredient composition, microcapsule and uses thereof and process of preparation
US20210093578A1 (en) * 2017-04-27 2021-04-01 Clover Corporation Limited Encapsulated nutritional and pharmaceutical compositions
CN107296278A (en) * 2017-07-10 2017-10-27 北京素维生物科技有限公司 A kind of function nutrition hardening agent composition and preparation method thereof
CN107594597B (en) * 2017-07-31 2020-05-12 浙江新和成股份有限公司 A kind of fat-soluble nutrient microcapsule and preparation method thereof
WO2019121493A1 (en) 2017-12-20 2019-06-27 Dsm Ip Assets B.V. Spray-dried particle comprising polyunsaturated fatty acids
CN120549885A (en) * 2018-07-24 2025-08-29 科劳弗股份有限公司 Protein encapsulation of nutritional and pharmaceutical compositions
CN111150086B (en) * 2019-12-31 2022-02-18 西昌市正中食品有限公司 Embedding wall material, and embedding process and application of microcapsule tartary buckwheat flavone
JP2023524350A (en) * 2020-03-02 2023-06-12 ニューバーシス・リミテッド Stable food-grade microcapsules for the delivery of labile and food-incompatible active ingredients into foods
CN116326779B (en) * 2023-04-17 2023-09-12 武汉星辰现代生物工程有限公司 Lutein preparation and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9445997B2 (en) * 2007-12-21 2016-09-20 Basf Se Microcapsules comprising a fat-soluble active substance

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1035319B (en) † 1952-05-07 1958-07-31 Hoffmann La Roche Process for the production of a powder containing vitamins
JPS5917949A (en) * 1982-07-20 1984-01-30 Asahi Denka Kogyo Kk Food containing highly unsaturated fatty acid
JPS6049097A (en) 1983-08-29 1985-03-18 日本油脂株式会社 Powdery fat
DE3702031A1 (en) † 1987-01-24 1988-08-04 Basf Ag METHOD FOR PRODUCING MICRODISPERSE FISH OIL PREPARATIONS
EP0385081B1 (en) * 1989-02-09 1993-08-11 Societe Des Produits Nestle S.A. Dried fat emulsion product and method of producing the same
JPH0730354B2 (en) 1989-05-19 1995-04-05 三協食品工業株式会社 Powder of highly unsaturated fatty acid-containing oil and fat and method for producing the same
JPH04502404A (en) * 1989-10-23 1992-05-07 ユニリーバー・ナームローゼ・ベンノートシャープ Dry solid composition containing lipids
DK546289D0 (en) † 1989-11-02 1989-11-02 Danochemo As carotenoid
ATE109761T1 (en) 1990-04-16 1994-08-15 Eastman Chem Co PROCESS FOR PREPARATION OF RESORCINOL BIS(HYDROXY-ETHYL) ETHER.
DK88692D0 (en) 1992-07-06 1992-07-06 Danochemo As PROCEDURE FOR MANUFACTURING MICROCAPPLES
JPH07305088A (en) 1994-05-13 1995-11-21 Nippon Oil & Fats Co Ltd Powdery oil and fat composition
PH12001000675B1 (en) 2000-04-04 2009-09-22 Australian Food Ind Sci Ct Encapsulation of food ingredients
AR039170A1 (en) * 2002-03-28 2005-02-09 Bio Dar Ltd DHA AND ROMERO CO-GRANULES AND METHODS OF USE
US7431986B2 (en) * 2002-07-24 2008-10-07 General Mills, Inc. Encapsulation of sensitive components using pre-emulsification
MX2007007181A (en) 2004-12-21 2007-08-14 Firmenich & Cie Encapsulated polyunsaturated fatty acids.
EP1938807A1 (en) 2006-12-22 2008-07-02 Basf Se Reactive powdering
EP1935410A1 (en) 2006-12-22 2008-06-25 Basf Se Microcapsules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9445997B2 (en) * 2007-12-21 2016-09-20 Basf Se Microcapsules comprising a fat-soluble active substance

Also Published As

Publication number Publication date
DK2234502T4 (en) 2021-10-11
CN101902922A (en) 2010-12-01
JP2014155490A (en) 2014-08-28
AU2008340061B2 (en) 2011-07-14
WO2009080702A1 (en) 2009-07-02
EP2234502A1 (en) 2010-10-06
CN101902922B (en) 2013-11-06
ES2632132T5 (en) 2021-12-27
EP2234502B2 (en) 2021-07-28
US9445997B2 (en) 2016-09-20
AU2008340061A1 (en) 2009-07-02
ES2632132T3 (en) 2017-09-11
DK2234502T3 (en) 2017-07-31
EP2234502B1 (en) 2017-04-12
JP2011508591A (en) 2011-03-17
US20110014288A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
US9445997B2 (en) Microcapsules comprising a fat-soluble active substance
EP1066761B1 (en) Compositions containing fat-soluble substances in a carbohydrate matrix
Fadini et al. Innovative strategy based on combined microencapsulation technologies for food application and the influence of wall material composition
EP1713575B1 (en) Aqueous dispersion and its use
Chang et al. Stability and in vitro release behaviour of encapsulated omega fatty acid-rich oils in lentil protein isolate-based microcapsules
US20100247713A1 (en) Beta + hydrolyzed lecithin
Singh et al. Encapsulated oil powder: Processing, properties, and applications
US20100260894A1 (en) Pulverous formulation of a fat-soluble active ingredient
JP4934840B2 (en) Fat-and-sugar powder material of fat-soluble vitamin or fat-soluble vitamin-like substance and method for producing the same
KR20180128025A (en) Nano-capsules containing lipid-soluble active ingredients, method for their preparation and uses thereof
JP6954917B2 (en) Polyphase active substance preparation
US20100272861A1 (en) Pulverous formulation of a fat-soluble active ingredient
US20100272862A1 (en) Pulverous formulation of a fat-soluble active ingredient
WO2008077401A1 (en) Reactive powdering
AU2019310346A1 (en) Protein encapsulation of nutritional and pharmaceutical compositions
WO2008077402A1 (en) Microcapsules
Fi̇li̇z et al. Spray Chilling Based Microencapsulation of Sulforaphane: Process Optimization and Release Dynamics
Augustin et al. Spray‐Dried Dairy‐Based Emulsions for the Delivery of Bioactives

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION